Vol 54, No 6 (2023)
Original research article
Published online: 2023-10-30

open access

Page views 406
Article views/downloads 168
Get Citation

Connect on Social Media

Connect on Social Media

Early mortality, kidney failure, and venous thromboembolism in patients with multiple myeloma: a single-center analysis

Marek Paweł Rodzaj1, Magdalena Anna Rodzaj2, Martyna Marcelina Rodzaj3
Acta Haematol Pol 2023;54(6):406-410.


Introduction: The objectives were to assess early mortality, the prevalence of kidney failure, venous thromboembolism (VTE), and to assess overall survival (OS) in patients with multiple myeloma (MM). Material and methods: A retrospective analysis of clinical and laboratory parameters in 413 patients with MM treated between 2006 and 2017. Results: The early mortality rate in the study group was 13% (57 of the 413 patients). Mortality rates were higher in men [odds ratio (OR) = 1.4] (p = 0.015), patients with kidney failure (OR = 9.1) (p = 0.001), and patients with significant proteinuria and immunoglobulin A secretion (OR = 1.3). Early mortality was not associated with age, lactate dehydrogenase levels, or hemoglobin levels at diagnosis. Patients with kidney failure at diagnosis of MM had lower total protein levels (p <0.001) and higher proteinuria levels (p <0.001) than the remaining patients. The 5-year OS in patients with kidney failure was 20% vs. 50% in those without kidney failure (p  0.001). VTE was reported in 38 patients (10.7%). There was no association between VTE and the patient’s age, kidney failure, urinary protein levels, type of monoclonal protein, stage of MM according to the International Staging System, or type of induction therapy. The median OS in the study group was 4.08 years. There was no correlation between VTE and OS in patients undergoing autologous hematopoietic stem cell transplantation. Conclusions: The use of novel drugs with a different mechanism of action in the treatment of MM has led to an improvement in survival rates, with an increase in median OS from 3–4 years to 5–7 years over the past 10 years. Still, it is estimated that 25% of patients die within less than 2 years from diagnosis.

Article available in PDF format

View PDF Download PDF file


  1. Vincent Rajkumar S. Multiple myeloma: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol. 2014; 89(10): 999–1009.
  2. Terebelo H, Srinivasan S, Narang M, et al. Recognition of early mortality in multiple myeloma by a prediction matrix. Am J Hematol. 2017; 92(9): 915–923.
  3. Charliński G, Tyczyńska A, Małecki B, et al. Risk factors and causes of early mortality in patients with newly diagnosed multiple myeloma in a "real-world" study: experiences of the Polish Myeloma Group. Pol Arch Intern Med. 2021; 131(6): 527–534.
  4. Moreau P, San Miguel J, Sonneveld P, et al. ESMO Guidelines Committee. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(suppl_4): iv52–iv61.
  5. Dimopoulos MA, Roussou M, Gkotzamanidou M, et al. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia. 2013; 27(2): 423–429.
  6. Moreau P. How I treat myeloma with new agents. Blood. 2017; 130(13): 1507–1513.
  7. Dmoszyńska A, Walter-Croneck A, Pieńkowska-Grela B, et al. Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2016. Acta Haematol Pol. 2016; 47(2): 39–85.
  8. Zangari M, Fink L, Zhan F, et al. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens. Clin Lymphoma Myeloma Leuk. 2011; 11(2): 228–236.
  9. Dancy E, Garfall A, Cohen A, et al. Clinical predictors of T cell fitness for CAR T cell manufacturing and efficacy in multiple myeloma. Blood. 2018; 132(Suppl 1): 1886–1886.
  10. Cohen AT, Katholing A, Rietbrock S, et al. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study. Thromb Haemost. 2017; 117(1): 57–65.
  11. Kraaijpoel N, Carrier M. How I treat cancer-associated venous thromboembolism. Blood. 2019; 133(4): 291–298.
  12. Timp JF, Braekkan SK, Versteeg HH, et al. Epidemiology of cancer-associated venous thrombosis. Blood. 2013; 122(10): 1712–1723.
  13. Prandoni P, Lensing AWA, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002; 100(10): 3484–3488.
  14. Kraaijpoel N, Nisio MDi, Mulder FI, et al. Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial. Thromb Res. 2018; 164: S223.
  15. Khorana AA, Noble S, Lee AYY, et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost. 2018; 16(9): 1891–1894.
  16. Samuelson Bannow BT, Lee A, Khorana AA, et al. Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH. J Thromb Haemost. 2018; 16(6): 1246–1249.